Ticagrelor was non-inferior to DAPT for the incidence of major adverse cardiovascular and cerebrovascular events. 2.

Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...

In two cohorts from the UK Biobank and the National Health and Nutrition Examination Survey (NHANES), there was an increased ...

In a randomized double-blind placebo-controlled study, naldemedine use was associated with constipation prevention and a ...

Machine learning (ML) models developed by Lehmann and colleagues used driving characteristics and head motion data to detect ...

In this cohort study involving noncirrhotic patients with chronic hepatitis B, a new prognostic model based on viral load was ...

Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...

Relutrigine resulted in a 46% reduction in seizures and seizure freedom in 30% of patients. Patients also experienced ...

In veterans with spinal cord injuries, exoskeletons showed no clear benefits (medical, physical or psychological) compared to ...

Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated ...

1. In this retrospective observational cohort study of children in St. Louis, those with the highest risk of firearm injury ...